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ABSTRACT
Objective To update the EULAR 2020 systematic literature 
review (SLR) on efficacy and safety of immunomodulatory 
agents in SARS- CoV- 2 infection.
Methods As part of a EULAR taskforce, a systematic 
literature search update was conducted from 11 December 
2020 to 14 July 2021. Two reviewers independently 
identified eligible studies and extracted data on 
efficacy and safety of immunomodulatory agents used 
therapeutically in SARS- CoV- 2 infection at any stage of 
disease. The risk of bias (RoB) was assessed with validated 
tools.
Results Of the 26 959 records, 520 articles were eligible 
for inclusion. Studies were mainly at high or unclear RoB. 
New randomised controlled trials (RCTs) on tocilizumab 
clarified its benefit in patients with severe and critical 
COVID- 19, mainly if associated with glucocorticoids. There 
are emergent data on the usefulness of baricitinib and 
tofacitinib in severe COVID- 19. Other therapeutic strategies 
such as the use of convalescent plasma and anti- SARS- 
CoV- 2 monoclonal antibodies showed efficacy in subjects 
not mounting normal anti- SARS- CoV- 2 antibody responses.
Conclusion This new SLR confirms that some 
immunomodulators (tocilizumab and JAK inhibitors) 
have a role for treating severe and critical COVID- 19. 
Although better evidence is available compared with the 
previous SLR, the need of RCT with combination therapy 
(glucocorticoids+anti- cytokines) versus monotherapy 
with glucocorticoids still remains alongside the need 
for standardisation of inclusion criteria and outcomes to 
ultimately improve the care and prognosis of affected 
people. This SLR informed the 2021 update of the EULAR 
points to consider on the use of immunomodulatory 
therapies in COVID- 19.
INTRODUCTION
The SARS- CoV- 2 pandemic has chal-
lenged the global healthcare system. Severe 
COVID- 19 pneumonia is associated with 
inflammation and immunothrombosis that 
may be treatable with immunomodulatory 
therapies but optimal treatment and timing 
is incompletely understood. Our previous 
systematic literature review (SLR)1 noted that 
despite the extremely large number of avail-
able studies, randomised controlled trials 
(RCTs) were few and most articles were of 
Key messages
What is already known about this subject?
 ► Several compounds with immunomodulatory activity 
have been tested in patients with SARS- CoV- 2 infec-
tion at various stages of the disease.
 ► Randomised controlled trials (RCTs) are available 
only for a few immunomodulatory compounds/strat-
egies, sometimes with conflicting results, and most-
ly for moderate to severe/critical COVID- 19.
What does this study add?
 ► By updating the previous systematic literature re-
view (SLR), all the new RCTs published up until July 
2021 were collected. The efficacy of glucocorticoids 
and tocilizumab in severe and critical COVID- 19 was 
clarified and potentially new promising therapeutic 
approaches were described.
 ► There are emergent data on the usefulness of ba-
ricitinib and tofacitinib in severe COVID- 19, mainly if 
associated with glucocorticoids.
 ► Other therapeutic strategies such as the use of con-
valescent plasma and anti- SARS- CoV- 2 monoclonal 
antibodies seem to be useful only in selected sub-
groups of patients.
How might this impact on clinical practice or 
further developments?
 ► This SLR informed the 2021 update of the EULAR 
points to consider for the use of immunomodulatory 
therapy in COVID- 19.
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lower level of evidence and at high risk of bias (RoB). 
Data on efficacy (or lack thereof) of some compounds 
such as hydroxychloroquine (HCQ) were consistent 
across studies; however, for other drugs, such as tocili-
zumab (TCZ), both positive and negative results were 
reported without a strong signal in either direction.1 
Furthermore, data emerging from the ‘grey literature’, 
either in full as preprints or in part via press releases, 
added a layer of complexity underscoring the evolving 
nature of COVID- 19 where contradictory findings were 
often reported.
Since new studies are continuously published, overar-
ching institutions regularly update their recommenda-
tions for the management of COVID- 19.2 3 Similarly, we 
conducted an update of our SLR in order to inform the 
2021 update of the EULAR points to consider for the use 
of immunomodulatory therapy in COVID- 19.
METHODS
Search methodology
Based on the same research questions of the original SLR 
and using the same systematic search strategy,1 a search 
was performed in MEDLINE, Embase, The Cochrane 
Database of Systematic Reviews, CENTRAL and CINAHL. 
The search was conducted from 11 December 2020 (cut- 
off date of the previous SLR) to 14 July 2021. The PubMed 
Similar Articles tool was also used, and a crosscheck of 
the key scientific journals in general medicine and immu-
nology was performed. Non- peer- reviewed literature was 
excluded given this SLR aimed at informing recommen-
dations. However, given the rapid evolution of knowl-
edge on COVID- 19 treatment, a parallel hand search of 
‘grey literature’, restricted to RCT not yet published in 
peer- reviewed journals but accessible in press releases 
or in extenso in preprint repositories, was performed. 
These not yet published RCTs are presented separately 
and were not used to inform the points to consider. We 
also conducted a new search to explore the efficacy and 
safety of anti- SARS- CoV- 2 monoclonal antibodies (mAbs) 
in infected subjects up to 14 July 2021 (online supple-
mental text 1).
Study selection, data collection and assessment of RoB
Original research articles of any study design, published 
in English, in peer- reviewed journals, addressing adults 
with proven SARS- CoV- 2 infection treated with one or 
more immunomodulatory agent or with anti- SARS- CoV- 2 
mAbs, were eligible. Two reviewers (AA and AN) inde-
pendently assessed titles and abstracts according to the 
predetermined eligibility criteria, followed by full- text 
review. Discrepancies were resolved by discussion and 
the task force methodologist (PMM) was consulted in 
the case of uncertainties. Data on patient characteris-
tics, investigated drug and administration scheme, and 
comparators and outcomes were extracted, as in the 
previous SLR. Whenever possible, risk ratios (RRs) and 
corresponding CIs were calculated. The RoB was assessed 
using validated tools.
RESULTS
Of the 26 959 records yielded by the search on immu-
nomodulatory therapies, 711 were selected for full- text 
review and 3 additional articles were identified by hand- 
search. Of these, 520 articles on 33 therapeutic strat-
egies met the inclusion criteria (online supplemental 
tables 1 and 2). Robust evidence was mostly available for 
moderate- to- severe/critical COVID- 19.
Of the 275 records yielded by the search on anti- SARS- 
CoV- 2 mAbs, 39 were selected for full- text review and 19 
met the inclusion criteria (online supplemental table 3). 
The best evidence available for each compound is shown.
RCT data in patients with moderate to severe/critical 
COVID-19
A total of 37 RCTs, all at high or unclear RoB, evaluating 
14 therapeutic approaches in severe/critical COVID- 19 
were retrieved by the SLR (online supplemental table 4).
Antimalarials
Eleven new RCTs were retrieved by the SLR search update, 
adding to the existing eight RCTs on HCQ included in 
the previous SLR. Out of these 11 new studies, 4 have 
been stopped early for futility,4–7 2 have been stopped 
for harmful effects of one or several compounds in the 
intervention arms,8 9 and 1 is underpowered,10 hence 
the results are not described in this manuscript. Out of 
the six studies that included patients with moderate to 
severe COVID- 19, one compared HCQ to chloroquine 
or ivermectine showing no efficacy on death, progres-
sion to invasive mechanical ventilation (IMV) or admis-
sion to intensive care unit (ICU) at day 90.11 The second 
study explored the efficacy and safety of adding either 
HCQ, lopinavir- ritonavir or a combination of the two to 
standard of care (SOC) in critically ill patients.12 One of 
the major findings of this trial is a significant reduction 
of survival in all three intervention arms compared with 
SOC (OR 0.65, 95% CI 0.45 to 0.95; OR 0.56, 95% CI 0.30 
to 0.89; and OR 0.36, 95% CI 0.17 to 0.73, respectively), 
suggesting a harmful role of lopinavir- ritonavir and HCQ 
(tables 1 and 2).
Glucocorticoids
Three new RCTs on glucocorticoids (GCs) were retrieved 
by the SLR update. Unfortunately, all three studies failed 
to recruit the target number of subjects allowing the 
trials to be sufficiently powered and therefore were inter-
rupted early and no conclusion could be drawn from the 
results.13–15
IL-6R inhibitors
The search update retrieved seven new RCTs on tocili-
zumab (TCZ)16–22 including COVACTA,18 REMAP- CAP,19 
RECOVERY,20 EMPACTA22 and the post hoc analysis of 
the CORIMUNO- TOCI- 1 trial at day 90 on the subgroup 
 on N
ovem










pen: first published as 10.1136/rm






















































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/rm

































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/rm






5Alunno A, et al. RMD Open 2021;7:e001899. doi:10.1136/rmdopen-2021-001899
Infections
of patients with C reactive protein (CRP) >150 mg/L.21 
Among these studies, REMAP- CAP19 (n=353 TCZ +SOC, 
n=42 SARI+SOC, n=402 SOC) RECOVERY20 (n=2094 
TCZ +SOC group and n=2022 in SOC group) and 
the post hoc analysis of CORIMUNO- TOCI- 121 (n=64 
TCZ +SOC and n=67 SOC) showed a reduction of death 
Table 2 Effect of immunomodulatory therapies on ventilation. Results from randomized controlled trials in moderate to 





(days) N treated Results RoB













HR (95% CI) 0.18 (0.06 to 0.59)
Unclear
SOC 67




RR (95% CI) 0.84; 0.77 to 0.92
Unclear
SOC 2022
REMAP- CAP19 TCZ+SOC 21 353 CV and respiratory organ support- 
free days OR (95% credible interval)
1.64 (1.25 to 2.14)
Unclear
SOC 402
COVACTA18 TCZ+SOC 28 294 Clinical status on 7- point ordinal 
scale
−1.0; 95% CI −2.5 to 0; p=0.31
Unclear
PBO+SOC 144
EMPACTA22 TCZ+SOC 28 249 Progression to IMV or death:
HR (95% CI) 0.56 (0.33 to 0.97)
Unclear
PBO+SOC 128
Sarilumab Lescure et al23 SARI 200 +SOC 60 159 Need of NIV/IMV
26 (20); RR (95% CI) 1.06 (0.6 to 1.9);





REMAP- CAP19 SARI+SOC 21 42 CV and respiratory organ support- 
free days OR (95% credible interval)
Unclear
SOC 402 1.76 (1.17 to 2.91)





Colchicine Lopes et al28 COL+SOC 7 36 Need of oxygen therapy
3 (9)
15 (42)
RR (95% CI) 0.2 (0.06 to 0.63)
High
PBO+SOC 36
Tofacitinib Guimarães et al30 TOFA+SOC 28 144 Death or respiratory failure
26 (18)
42 (29)
RR (95% CI) 0.63 (0.4 to 0.97)
Unclear
PBO+SOC 145
Mavrilimumab Cremer et al36 MAV+SOC 60 21 Need of IMV
5 (24)
4 (21)
RR (95% CI) 1.13 (0.3 to 3.6)
High
SOC 19
Interferon beta Darazan et al40 IFNbeta1a+SOC 21 20 IMV





Convalescent plasma Balcells et al42 Early CP +SOC 14 28 IMV
5 (18)
2 (7)
RR (95% CI) 3.04 (0.54 to 17.17)
High
Differed/no CP+SOC 30





Results from randomised controlled trials in moderate to severe and critical COVID- 19.
CANAK, canakinumab; COL, colchicine; CP, convalescent plasma; CQ, chloroquine; CRP, C reactive protein; CV, cardiovascular; HCQ, hydroxychloroquine; IFN, interferon; IMV, 
invasive mechanical ventilation; IVIG, intravenous immunoglobulins; MAV, mavrilimumab; NIV, non- invasive ventilation; PBO, placebo; RoB, risk of bias; RR, relative risk; SARI, 
sarilumab; SOC, standard of care; TCZ, tocilizumab; TOFA, tofacitinib.
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at Day 28 (RR 0.82, 95% CI 0.75 to 0.90), day 21 (RR 0.27, 
95% CI 0.12 to 0.72) and day 90 (CORIMUNO- TOCI- 1 
in patients with CRP >150 mg/L), respectively (RR 
0.64, 95% CI 0.25 to 1.65). Of note, in all these studies 
except the post hoc analysis of CORIMUNO- TOCI- 1,21 
where patients received only oxygen between 3 and 15 L, 
at baseline the patients were receiving oxygen (26% to 
46%), NIV (31% to 48%) or MV (5%–30%). In addi-
tion to the efficacy on death, reduction of progression 
to MV or death at day 2120 or day 9021 in CORIMUNO- 
TOCI- 1 in patients with CRP >150 mg/L or an increase 
in cardiovascular or respiratory support- free days19 were 
observed. COVACTA18 comparing TCZ +SOC (n=294) to 
PBO+SOC (n=144) did not show any efficacy on death at 
day 28 (RR 1.01, 95% CI 0.7 to 1.5) or improvement of 
clinical outcome (RR 1.01, 95% CI 0.7 to 1.5). The study 
from Soin et al16 did not show efficacy on death or disease 
progression at day 14 or day 28.
Of note, all studies except Soin et al were evaluated at 
unclear RoB. One study was underpowered and there-
fore results are not detailed.17
The evidence regarding sarilumab is scarcer as the 
search retrieved two RCTs at unclear RoB; one comparing 
sarilumab to SOC,19 and the other comparing sarilumab 
to PBO.23 The REMAP- CAP trial19 included a small arm 
comparing sarilumab (n=44 patients) to SOC (n=402); 
most patients in the sarilumab arm were receiving NIV 
(48%) at baseline. The study showed a reduction in death 
and CV and respiratory organ support- free days (RR 1.76, 
95% CI 1.17 to 2.91).18 The other RCT23 compared two 
dosages of sarilumab (200 and 400 mg) to PBO, and 
showed no efficacy on death (Sari 200: RR 1.13, 95% CI 
0.5 to 2.4; Sari 400: RR 0.98, 95% CI 0.5 to 2.1), progres-
sion to MV (Sari 200: RR 1.06, 95% CI 0.6 to 1.9; Sari 400: 
RR 1.2, 95% CI 0.7 to 2.2) or admission to ICU (Sari 200: 
RR 0.83, 95% CI 0.3 to 2.1; Sari 400: RR 1.2, 95% CI 0.5 to 
2.7).
Of note, there is a high heterogeneity among trials in 
terms of the proportion of patients receiving GCs as part 
of SOC. An important difference was observed between 
trials starting before and after the positive results of the 
GC arm of the RECOVERY trial.24 It is noteworthy that 
while in two positive RCTs, a high percentage of patients 
were receiving GCs (82% to 93%),19 20 in an important 
negative trial, COVACTA,18 which failed to show efficacy 
in reducing death or improving clinical status, only up to 
50% of patients were receiving GCs. In addition, a recent 
RCT meta- analysis published in JAMA concluded that 
TCZ reduced all- cause mortality (OR 0.83, 95% CI 0.72 to 
0.94) and progression to MV, ECMO or death (OR 0.74, 
95% CI 0.66 to 0.82) at day 28.25
Of interest, when analysing the subgroup of patients 
receiving GCs compared with those who did not, death 
at day 28 was only significantly reduced in the TCZ group 
receiving GCs (RR 0.77, 95% CI 0.68 to 0.87) p=0.008) 
but neither in the TCZ group not receiving GCs (RR 1.06, 
95% CI 0.85 to 1.33) nor in the SARI group regardless of 
their GCs status (RR 0.77, 95% CI 0.64 to 1.31, p=0.34).
IL-1 inhibitors
As far as anakinra in concerned, only one study at high 
RoB was retrieved by the search update. This corre-
sponded to a preprint that was subsequently published 
during the preparation of this manuscript.26 This study 
included patients with COVID- 19 pneumonia and soluble 
urokinase plasminogen activator elevations at 6 ng/mL 
or above, which is considered as a predictor of unfavour-
able outcome. In this population, anakinra 100 mg subcu-
taneous for 7–10 days increased the number of patients 
recovered (RR 1.9, 95% CI 1.5 to 2.5), according to the 
WHO 11- point clinical progression ordinal scale, and 
decreased mortality at day 28: 3.2% vs 6.9% (HR=0.45, 
p=0.045).
Regarding canakinumab, no RCT was retrieved by the 
search update but while writing this manuscript the CAN- 
COVID study was published27 and it demonstrated that 
the addition of canakinumab to SOC did not provide any 
benefit on survival at 29 days.
Colchicine
The SLR identified one small RCT at high RoB.28 The 
study reported that colchicine 0.5 mg three times per day 
for 5 days followed by 0.5 mg two times per day for 5 days 
in addition to SOC was able to reduce the duration of 
hospitalisation and the need of oxygen therapy. However, 
no significant effect was observed with regard to admis-
sion to ICU. In addition, it is important to mention 
that the colchicine arm of the RECOVERY trial closed 
in March 2021 since an interim analysis demonstrated 
no convincing evidence that further recruitment would 
provide conclusive evidence of benefit in any prespeci-
fied subgroup.29
JAK inhibitors
One RCT30 comparing tofacitinib or placebo in addi-
tion to SOC reported a significant improvement of the 
composite outcome of respiratory failure or mortality at 
day 28 (RR 0.63, 95% CI 0.41 to 0.97) in a population 
where the large majority of patients (about 90%) received 
GCs as part of SOC.
Regarding baricitinib, the SLR retrieved no RCT but 
important information emerged from the grey liter-
ature. The addition of baricitinib to SOC, where the 
large majority of patients received GC as part of SOC, 
proved ineffective in improving the composite outcome 
of progression to NIV/IMV or death by day 28 (OR 
0.85, 95% CI 0.67 to 1.08; p=0.18) (COV- BARRIER trial 
published as a preprint on 3 May 2021 and subsequently 
published in a peer- reviewed journal while preparing this 
manuscript).31 However, the study found a decrease of 
28- day all- cause mortality: 8% vs 13% (HR 0.57; 95% CI 
0.41 to 0.78; p=0.0018). Finally, with regard to the combi-
nation of baricitinib and remdesivir, the Fourth iteration 
of the Adaptive COVID- 19 Treatment Trial (ACTT- 4) 
comparing baricitinib +remdesivir+placebo versus remde-
sivir +dexamethasone+placebo met predefined futility 
criteria in an interim analysis hence closed enrolment in 
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April 2021. This was announced by a press release and 
interim data are not available.32
A small multiple ascending dose study of the inhaled 
pan- JAK inhibitor nezulcitinib provided encouraging, 
although not significant results, on mortality and progres-
sion to IMV in hospitalised patients with COVID- 19 
requiring oxygen therapy and receiving GC as part of 
SOC.33 Nezulcitinib 3 mg is currently under investigation 
in a larger trial.34 No new RCT data on other JAKs were 
retrieved but the negative RUXCOVID trial data were 
published on 21 June 2021 on  clinicaltrials. gov website 
and demonstrated that the addition of ruxolitinib to 
SOC did not provide any benefit on any clinical outcome 
at day 28.35
GM-CSF inhibitors
In the previous SLR, no RCTs on granulocyte- 
macrophage colony- stimulating factor (GM- CSF) inhib-
itors were identified. The update allowed identifying a 
small RCT investigating mavrilimumab in addition to 
SOC in hospitalised patients with COVID- 19 receiving 
oxygen therapy or NIV but not IMV.36 This study did not 
provide evidence of efficacy for this treatment strategy 
but one RCT identified in the grey literature showed 
a 65% reduction in risk of IMV/death (p=0.02) and a 
marked, although not significant, reduction in risk of 
death with mavrilimumab versus placebo (p=0.07).37 
The search in the grey literature also provided informa-
tion on another GM- CSF inhibitor, lenzilumab, which 
was used in addition to SOC in hypoxic hospitalised 
patients (receiving or not oxygen therapy) was superior 
to placebo +SOC in improving survival without venti-
lation. Of interest, patients with CRP <150 mg/L and 
age <85 years were those who had the greatest benefit 
from lenzilumab.38 In addition, a press release reported 
on the GM- CSF inhibitor otilimab and the data of a 
preplanned analysis of the OSCAR trial.39 Patients aged 
70 and over receiving otilimab in addition to SOC had a 
higher probability of being alive and free of respiratory 
failure at day 28 compared with those in the same age 
range receiving placebo in addition to SOC. Further-
more, 60- day mortality was significantly lower in otilimab- 
treated patients aged 70 and over.
Type I interferons
Two small RCTs at high RoB did not observe any benefit 
after adding interferon beta to SOC.40 41
Convalescent plasma and non-SARS-CoV-2 immunoglobulins
Five RCTs (two at high and two at unclear RoB) were 
retrieved by the search update and one of them was 
underpowered.42–45 None of the studies showed clear 
efficacy on mortality or other major clinical outcomes by 
adding convalescent plasma to SOC. One small RCT at 
high RoB on the use of non- SARS- CoV- 2 immunoglobu-
lins was also retrieved by the search update showed some 
benefit in reducing hospital or ICU stay.46
Anti-SARS CoV-2 monoclonal antibodies
The new SLR identified one RCT enrolling hospitalised 
patients with moderate- to- severe COVID- 19 and assessing 
bamlavimab monotherapy.47 The study failed to provide 
any benefit on clinical outcomes (eg, 90- day mortality).
RCT data in patients with mild COVID-19 (non-hospitalised or 
hospitalised without oxygen therapy)
Two RCTs assessing HCQ in patients with mild to moderate 
COVID- 19 were retrieved(table 3). One was stopped for 
futility,48 while the other one compared two therapeutic 
strategies: HCQ or favipiravir in a small sample of hospital-
ised patients (n=50 in each group) with mild to moderate 
disease not receiving oxygen supplementation, showing 
no efficacy on SARS- CoV- 2 PCR negativity development or 
regression of abnormal radiography.49 The latter article was 
retracted while preparing this manuscript.50
A large RCT at unclear RoB enrolling non- hospitalised 
patients with mild COVID- 19 demonstrated weak improve-
ment of the composite outcome death or hospitalisation 
with colchicine.51
Two small RCTs, one at high and one at unclear RoB, did 
not detect any differences following the administration of 
one dose of PEG- IFN lambda or placebo in non- hospitalised 
patients with mild COVID- 19.52 53
Finally, the administration of one dose of PEG IFN-α2b 
instead of placebo in addition to SOC allowed a higher 
number of hospitalised patients with moderate COVID- 19 
to achieve clinical improvement on day 15.54
As far as mAb against the SARS- CoV- 2 spike protein are 
concerned, the SLR identified three RCTs enrolling non- 
hospitalised patients with mild to moderate COVID- 19.55–57 
The combination of bamlanivimab and etesevimab, as well 
as of casirivimab and imdevimab administrated within the 
first week after symptom onset was able to significantly 
reduce viral load. However, casirivimab and imdevimab 
were effective only in patients seronegative at baseline. 
Conversely, bamlanivimab monotherapy failed to signifi-
cantly reduce viral load in non- hospitalised patients. In addi-
tion, the results of the antiviral arm of the RECOVERY trial, 
retrieved in the grey literature,58 showed that casirivimab 
and imdevimab are also able to reduce 28- day mortality in 
seronegative patients (rate ratio=0.80, 95% CI 0.70 to 0.91, 
p=0.0010).
Data from observational studies and case reports
As summarised in online supplemental table 2 for several 
compounds, no RCTs were retrieved by the SLR update. 
Among these, two studies deserve to be commented being 
the only few of this kind available so far. Two retrospective 
trials at high of bias compared the efficacy of methylpredni-
solone (MTP ≥1 mg/kg/day)54 or 250–500 mg for ≥3 days) 
versus dexamethasone (DEXA ≥6 mg for ≥7 days). Both 
studies showed a reduction of death in the group treated 
with MTP. For the study by Ko et al,59 only the subgroup 
receiving IMV had a lower RR (0.480, 95% CI 0.235 to 
0.956),54 while in the study from Pinson et al,60 the mortality 
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and transfer to ICU were numerically lower, although no 
statistical tests were presented.
DISCUSSION
The update of the SLR demonstrated that although a 
higher number of RCTs is now available assessing new 
immunomodulatory compounds, a knowledge gap on 
some therapeutic strategies and on mild- to- moderate 
COVID- 19 still exists and too many low quality/low level 
of evidence studies are being published. We therefore 
focused our attention on RCTs and not on observational 
studies that are still included in the SLR and reported for 
the sake of comprehensiveness but not discussed in detail 
in this manuscript.
The new RCTs demonstrated that tocilizumab and 
some JAK inhibitors, such as baricitinib and tofacitinib, 
are effective, particularly in association with GC. The role 
of tocilizumab was unclear based on the results gathered 
in the previous SLR since there was no strong positive 
signal in papers published in peer- reviewed journals 
while the largest positive study, the REMAP- CAP, had 
only been published as a preprint. The additional data 
from the tocilizumab arm of the RECOVERY trial, the 
post hoc analysis of the CORIMUNO- 19 TOCI- 1 and the 
meta- analysis of RCTs published in the JAMA helped clar-
ifying the scenario. Likewise, anti- IL6 receptor antibodies 
have received a strong recommendation from WHO in 
patients with severe and critical COVID- 19.61
As far as JAK inhibitors are concerned, the previous 
SLR included an article supporting the efficacy of baric-
itinib in combination with remdesivir and no evidence 
on tofacitinib was available. In this new SLR, the results 
from the COV- BARRIER trial with baricitinib and from 
an independent tofacitinib trial point to a possible JAK 
inhibition therapeutic application of these compounds, 
at least in some subgroups of patients (patients on 
oxygen, including high flow oxygen) but the grey liter-
ature pointed to non- efficacy of JAK- 2 inhibition. Like-
wise, selected patients may benefit from other strategies 
such as convalescent plasma and anti- viral monoclonal 
antibodies that seem to find a role only in seronegative 
patients with early disease.
It is important to note that heterogeneity across studies, 
in terms of outcomes, timepoints and SOC protocols still 
remains, although to a lesser extent. In particular, after 
the publication of the results from the GC arm of the 
RECOVERY trial, GCs were implemented in most SOC 
protocols and this allowed to better understand the 
potential of combining them with anti- cytokine mole-
cules in RCTs, although with the limitation of this not 
being a predefined study arm.
Furthermore, recently published studies may still 
include patient cohorts enrolled during the first wave 
and therefore with all the major pitfalls highlighted in 
our previous SLR.1
In conclusion, this SLR informed the EULAR initiative 
to update the points to consider on the use of immuno-
modulatory therapies in COVID- 19.62 Although better 
evidence is available compared with the previous SLR, 
the need for RCT with combination therapy (GC +anti- 
cytokines) versus monotherapy with GC still remains 
alongside the need for standardisation of inclusion 





(days) N treated Results RoB
Hydroxychloroquine Dabbous et al49 HCQ 14 50 2 successive negative 
SARS- CoV- 2 PCR 
tests 48 hours apart RR 
(95% CI) 1.17 (0.8 to 1.7)
Radiological 
abnormalities RR 
(95% CI) 1.20 (0.6 to 2.5)
High
Favipiravir 50
Colchicine Tardif et al51 COL 30 2235 RR (95% CI)
Death 0.56 (0.19 to 1.66)
Hospitalisation 0.75 
(0.57 to 0.99)
IMV 0.50 (0.23 to 1.07)
Unclear
PBO 2253
PEG- interferon alpha Pardit et al54 PEG- IFN alpha +SOC 15 20 Clinical improvement 








Feld et al53 PEG- IFN lambda- 1a 7 30 Negative RT- PCR, RR 
(95% CI)






Results from randomised controlled trials.
COL, colchicine; HCQ, hydroxychloroquine; IMV, invasive mechanical ventilation; PBO, placebo; PEG- IFN, pegylated interferon; RoB, risk of bias; RR, relative risk; 
RT- PCR, real time PCR; SOC, standard of care.
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criteria and outcomes to ultimately improve the care and 
prognosis of affected people.
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